Comparative trial on the therapeutic effectiveness of the new anthelmintic drug: ciclobendazole.
In a double-blind study in Cameroon the vermicidal effect of Ciclobendazole, a new Benzimidazole derivative, was evaluated and compared to Mebendazole. Ciclobendazole and Mebendazole were equally effective in the treatment of Ascaris and Hookworm infestations. An increase in the dosis of Ciclobendazole from 600 mg to 1200 mg did not lead to an improvement in the effectiveness. When treating trichuriasis significantly better results were achieved with Mebendazole (p = 0.01). Both drugs were tolerated equally well. Side effects, such as vomiting and diarrhoea, only occurred in a small percentage of cases.
D000328:Adult; D000724:Ancylostomiasis / Q000188:drug therapy; D000871:Anthelmintics / Q000009:adverse effects / Q000627:therapeutic use*; D001196:Ascariasis / Q000188:drug therapy; D001562:Benzimidazoles / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D014257:Trichuriasis / Q000188:drug therapy
D000871:Anthelmintics; D001562:Benzimidazoles